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INTRODUCTION 
 
Inflammatory diseases that occur in the pharynx, involv-
ing both adenoids and tonsils, are important not only for 
being very frequent but also because they often require 
minor surgery for their resolution (Pitrez, 2003). These 
anatomophysiological structures have immunological 
roles leading to production of antibodies, working in the 
local immunity of the pharynx and protection of the en-
tire human body. The most common etiologic agent of 
sore throats is Streptococcus pyogenes, an important 
pathogen of the beta-hemolytic group A which causes 
streptococcal pharyngitis (Bisno, 1997). The emergence 
of antibiotic-resistant bacterial strains and the poor pen-
etration of conventional chemical antibiotics in bacterial 
biofilms raise the need for safe and effective options of 
antimicrobial treatment (Gonzalez, 2001). The applica-
tion of bacteriophages (or cocktails therefrom) has been 
proposed as an alternative (or complement) to conven-
tional chemical antibiotics, allowing the release of natural 
predators of bacteria directly on these biofilms (Sulak-
velidze 2001). The major advantage of bacteriophage-
based antibiotherapy relative to its conventional chemical 
counterpart is that bacteriophages replicate at the site of 
infection, being available in abundance where they are 
needed the most. When compared with chemical antibiot-
ics, bacteriophages have other important advantages: (i) 
strong tissue permeability, (ii) bacteriophage concentra-
tion remains high at the focus of infection, continuously 
increasing with bacterial (host) presence, (iii) elimination 
of the focus of infection occurs only after eradication of 
the host bacterium, (iv) bacteriophages are fully compati-
ble with antibiotics and may act synergistically, (v) they 
are specific against the target bacteria, (vi) have a su-
perior ability to penetrate bacterial biofilms, inducing 
production of enzymes that hydrolyze the biofilm poly-
meric matrix, (vii) although bacteria can develop resist-
ance to bacteriophages, isolation of new lytic bacterio-
phages is much simpler and cheaper than developing a 
new chemical antibiotic (Sulakvelidze, 2001). In this re-
search effort, development of a biotechnological process 
for the inhalational administration of a bacteriophage 
cocktail (endotoxin free) was pursued, using strategies of 
nanoencapsulation within lipid nanovesicles (as forms of 
protection and stabilization (Ragoonanan 2007) of the 
bacteriophage against the immune system) to treat infec-
tious pathologies such as pharyngo-tonsillitis. This 
method of targeting may have a high potential for the 
treatment of bacterial infections of the respiratory tract, 
since inhalation therapy is considered to be favorable to 
certain respiratory infections because the aerosol is deliv-
ered directly at the site of infection, accelerating the ac-
tion of bacterial predators. Additionally, a smaller 
amount of bioactive substance is needed, thus preventing 
or reducing possible deleterious side effects. As a proof-
of-concept for the nanoencapsulation strategy, and since 
there is not yet available a strictly lytic bacteriophage (or 
cocktail of lytic bacteriophages) for Streptococcus pyo-
genes, a well-defined and characterized bacteriophage 
was utilized, viz. bacteriophage T4. In this context, 
water-in-oil-in-water (W/O/W) multiple emulsions are 
nanosystems in which dispersions of small water droplets 
within larger oil droplets are themselves dispersed in a 
continuous aqueous phase (Bibette 1999; García-Fuentes 
2002). Due to their compartimentalized internal structure, 
multiple emulsions present important advantages over 
simple O/W emulsions for encapsulation of bio-
molecules, such as the ability to carry both polar and non-
polar molecules, and a better control over releasing of 
therapeutic molecules (Srinivas 2010; Rawat 2008; Pays 
2002; Davis 1987; Hanson 2008; Ficheux 1998; Wang 
2006; Gutiérrez 2008). Bacteriophage T4 was entrapped 
within lipid nanovesicles integrating W/O/W multiple 
nanoemulsions, aiming at mimicking the multifunctional 
design of biology, optimized with several lipid matrices, 
poloxamers and stabilizing layer compositions. Physico-
chemical characterization of the optimized bacterio-
phage-encasing nanovesicle formulations encompassed 
determination of particle size, size distribution and parti-
cle charge, via Zeta potential analysis, surface morphol-
ogy via Cryo-SEM, and thermal analysis via DSC, 
whereas antimicrobial activity of the nanoemulsions pro-
duced were evaluated via the “spot-test” using appropri-
ate bacterial cultures. 
 
MATERIALS AND METHODS 
 
Preparation of multiple bacteriophage T4-Encasing 
lipid nanoemulsions. 
 
Production of multiple emulsions encompassing lipid 
nanovesicles with encased bacteriophage T4 was carried 
out using an Ultra Turrax (model T25D from IKA) under 
heating (ca 40 ºC). Lyophilized bacteriophage T4 was 
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suspended in the (inner) aqueous phase (Win) and then 
dispersed in the melted oil phase, via high-speed ho-
mogenization (10 min at 10000 rpm). The resulting W/O 
emulsion was further dispersed in the outer aqueous 
phase, via another homogenization cycle of 10 min. The 
inner aqueous phase encompassed HCl 10 mM, Tween 
80 and non-purified lyophilized bacteriophage T4 prepa-
ration (5 mg); the intermediate oily phase encompassed 
glycerol, Softisan™ 100 (from Sasol Olefins & Surfac-
tants GmbH, Hamburg, Germany) and soybean phospha-
tidylcholine; finally, the outer aqueous phase encom-
passed Lutrol™ F68 (poloxamer 188 from BASF, Ger-
many) and ultrapure water. 
 
Optimization of the nanoformulation. 
 
Optimization of the multiple lipid nanoemulsion pro-
ceeded via preparation of different emulsions with differ-
different concentrations of Tween 80 (50 to 75 mg) and 
different stabilizing layer compositions. 
 
Determination of hydrodynamic size (HS) and Zeta po-
tential (ZP). 
 
Determination of HS of the lipid nanovesicles produced, 
of the polydispersion index and of their ZP were carried 
out in a Zetasizer (model Nanoseries Nano-ZS) from 
Malvern Instruments. 
 
RESULTS AND DISCUSSION 
 
Several variables were studied, viz. lipid nature, 
poloxamer nature, soy lecithin concentration and Tween 
80 concentration. 
Replacement of the poloxamer (Lutrol™ F68) by Lutrol 
F-127 led to a substantial decrease (from more negative 
towards less negative values) in the negativity of the Zeta 
Potential of the lipid nanovesicles. 
Increasing Tween 80 concentration, up to 40% more of 
the departing concentration, led to more negative Zeta 
Potential values, but the lipid nanovesicles seemed to be 
unstable over storage time, with notorious disaggrega-
tion. 
The effect of simultaneously increasing the amounts of 
Tween 80 and lecithin were implicit in the high increase 
of Zeta Potential (from more negative towards less nega-
tive values), presumably due to accumulation of adsorbed 
ions at the particle surfaces. A lower concentration of 
Tween 80 proved to be suitable in producing lipid 
nanovesicles with stabler Zeta Potential and higher hy-
drodynamic sizes, throughout storage time. 
Both the Hydrodynamic size and Zeta Potential of the 
several nanoemulsions produced were evaluated and fol-
lowed throughout a prolonged storage at room tempera-
ture. 
Since we aimed at entrapping a bioactive lytic phage 
within the lipid nanovesicles, a lipid was chosen so as to 
melt down at a lower temperature, viz. Softisan 100™. 
The preliminary results obtained for the antimicrobial 
(lytic) properties of the optimized nanoemulsion encasing 
bacteriophage T4, showed an inhibition halo produced by 
the whole nanoemulsion. 
 
CONCLUSIONS 
 
In this research effort, development and optimization of 
lipid nanovesicles encasing bacteriophage-T4 was pur-
sued. A lipid with a mild melting temperature, encom-
passing medium-to-long chain fatty acid moieties was 
found most appropriate for the discontinuous oily phase. 
A homogenization timeframe of 10 min, the use of a low 
concentration of Tween 80, and low bacteriophage con-
centrations were found to be critical processing variables 
for producing stable nanovesicle dispersions with diame-
ters ranging from 115-145 nm and Zeta Potential values 
of ca. -16 mV. Inclusion of these multiple nanoemulsions 
in isotonic formulations for inhalational therapy of 
pharyngo-tonsillitis would possess inherent advantages, 
when compared with the current chemical antimicrobial 
approach, if bacteriophage-T4 were to be replaced by a 
lytic phage specific for Streptococcus pyogenes, in that 
bacteriophages are naturally harmless entities with bacte-
riostatic activity, without any toxicological risk for hu-
mans. 
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